This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vale, T. Articles by Lipsky, P. E. Search for Related Content PubMed PubMed Citation Articles by Vale, T. Articles by Lipsky, P. E.

Raf-induced Transformation Requires an Interleukin 1 Autocrine Loop

Department of Internal Medicine and Harold C. Simmons Arthritis Research Center [T. V., P. E. L.], and Department of Cell Biology and Neuroscience [T. T. N., M. A. W.], University of Texas Southwestern Medical Center, Dallas, Texas 75235-8884

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The c-Raf-1 serine/threonine protein kinase plays a critical role in the proliferation of most cell types that have been examined. As such, the Raf proto-oncogene is thought to play a central role in the development of human tumors. Although the c-raf-1 gene itself rarely appears to be mutated in human tumors, the kinase activity of Raf is frequently found to be more active in tumor cells, likely through constitutive activation of upstream activators of Raf. The downstream events triggered by Raf that are involved in transformation have been studied less extensively. We show in this study that Raf-induced transformation of NIH 3T3 cells requires the activation of the ubiquitously expressed transcription factor, nuclear factor-B, by Raf. Furthermore, through the use of CrmA, interleukin 1 (IL-1) receptor antagonist, and a dominant-negative form of TRAF6, we demonstrate a requirement for IL-1 production and signaling from the IL-1 receptor as necessary components of Raf-induced transformation. These results indicate that IL-1 may be used as an autocrine growth factor by a number of tumors in which activation of Raf plays an important role in transformation and suggest that blockade of IL-1 signaling may be an approach to limiting the growth of certain tumors.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
It is known that human cancer reflects the loss of a proper balance between cell death and cell proliferation such that cancer cells often show a resistance to apoptosis and can proliferate under conditions in which normal cells cannot. It is thought that these phenotypes are caused by the accumulation of mutations in a variety of genes whose products normally play a role in the biochemical pathways that regulate cell death and cell proliferation. One of the key pathways controlling cellular proliferation identified to date is the MAPK² pathway. This pathway is known to be regulated by Raf, which phosphorylates MEK1 and MEK2, which then directly phosphorylate ERK1 and ERK2 (1, 2, 3) . The ERKs then phosphorylate a variety of proteins, both in the cytosol and in the nucleus, which can regulate cell proliferation. Although the MAPK pathway appears to be critical for cell proliferation, we have found that the activation of MAPK by a constitutively active form of MEK is not sufficient to transform NIH 3T3 cells.³ However, activated forms of both Ras and Raf are capable of transforming NIH 3T3 cells. This suggests that both Ras and Raf are capable of activating at least one pathway required for transformation that MEK cannot activate.

Besides MEK, other targets of Raf that have been identified previously include Cdc25A, pp70 S6K, and NF-B, all of which are known to play key roles in cell proliferation (4, 5, 6, 7) . However, with the exception of MEK, the relevance of these in Raf-induced transformation have not yet been explored. In this study, the dependence of Raf-induced transformation on NF-B activation was explored using a dominant-negative form of IB. NF-B is a ubiquitously expressed transcription factor that consists of heterodimeric and homodimeric complexes (8) . These complexes are sequestered in the cytoplasm by IB, which is thought to function by masking the nuclear localization signal of NF-B (9 , 10) . A pair of related kinases, IKK and IKKß, has been identified recently that phosphorylate IB on Ser-32 and Ser-36, thereby targeting IB for ubiquitination and its subsequent degradation by the 26S proteasome, thus allowing NF-B to enter the nucleus (11, 12, 13, 14, 15, 16) . NF-B has been shown to play a role in the regulation of a variety of genes, including those encoding various cytokines, cell adhesion molecules, antiapoptotic genes, and many others (8 , 17) .

One gene in particular, which is induced by NF-B and could provide an explanation for the need for NF-B in Raf-induced transformation, is IL-1ß, as this factor is mitogenic for fibroblasts as well as a variety of other cell types (18, 19, 20) . The IL-1 family consists of three known members: IL-1, IL-1ß, and IL-1Ra. Both IL-1 and ß can bind to the p80 IL-1 receptor as agonists, whereas IL-1Ra functions as a pure receptor antagonist (19) . Both IL-1 and IL-1ß are synthesized as precursors that require cleavage to generate the mature forms (19) . Caspase-1 (IL-1ß converting enzyme) has been shown to be the protease responsible for cleaving the precursor form of IL-1ß, whereas calpain has been identified as a protease capable of cleaving the precursor form of IL-1 (21) . Both the immature and the mature form of IL-1 can activate the IL-1 receptor, whereas only the mature form of IL-1ß can activate the receptor (19 , 22) .

Although the nature of the signal transduction pathways triggered by activation of the IL-1R are ill-defined at this point and have not been completely delineated, the activation of NF-B, c-Jun NH₂-terminal kinase, p38, PI3K, and sphingomyelinase have all been demonstrated (19 , 23, 24, 25) . The activation of NF-B by IL-1 appears to involve the binding of IRAK to the IL-1R accessory protein MyD88 with the subsequent appearance of highly phosphorylated forms of IRAK (26 , 27) . IRAK then appears to associate with TRAF6, which itself binds to NIK, a kinase that activates IKK, thereby bringing about the activation of NF-B by IL-1 (28) . The role of this pathway in transformation mediated by Raf has not been examined previously.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cell Culture and Transfection.
NIH 3T3 cells were cultured in DMEM (Life Technologies, Inc.) supplemented with 10% calf serum (Life Technologies, Inc.) and maintained in a humidified chamber with 5% CO₂ at 37°C. Stable transfections of NIH 3T3 cells were done using the calcium phosphate method. Briefly, 1 x 10⁶ cells were plated in 100-mm dishes (Nunc) the day before transfection and fed with 10% calf serum 4–6 h before the transfection. NIH 3T3 genomic DNA was used in all transfections as carrier DNA. The precipitate was left on the cells for 16 h, followed by feeding the cells with fresh 10% calf serum. The cells were then split 1:4 on the following day into selective media: two plates with 10% calf serum supplemented with G418 (Life Technologies, Inc.) to a final concentration of 400 µg/ml for measuring transfection efficiency and analyzing protein expression and into two plates with 5% calf serum for focus formation assays. Transient transfections were done using Lipofectamine (Life Technologies, Inc.) according to the manufacturer’s instructions. Cells were serum-deprived in 0.5% calf serum for 48 h before lysis in 1x reporter lysis buffer (Promega). Luciferase assays were then performed according to the manufacturer’s instructions (Promega).

Construction of Expression Plasmids.
Murine IL-1Ra was removed as an EcoRI fragment from pBlueScript and cloned into the EcoRI site of pcI-neo (Promega) and checked for proper orientation. IL-1Ra was then removed from pcI-neo with NheI and NotI and cloned into pCEP4 (Invitrogen). pCEP4 CrmA was generated by removing the coding sequence from pcDNA3 with HindIII and XhoI. All other plasmids have been described previously (29) .

Western Blot Analysis.
To examine the levels of phosphorylated and total ERK, transiently transfected NIH 3T3 cells were lysed in boiling 1% SDS and 10 mM Tris (pH 7.5) and sonicated to reduce viscosity. Protein concentrations were measured with the D_C protein assay kit from Bio-Rad. Ten µg of protein were then subjected to SDS-PAGE electrophoresis, transferred to an Immobilon-P membrane (Millipore), blocked with 5% nonfat powdered milk, and then probed with anti-active ERK (Promega) and anti-ERK1 (Santa Cruz), which cross-reacts with ERK2. ECL (Amersham) was then performed according to the manufacturer’s protocol. To examine expression of RasV12, RafBXB, IBN, and TRAF6, pools of G418-resistant colonies of NIH 3T3 cells were lysed in boiling 1% SDS and 10 mM Tris (pH 7.5) and sonicated to reduce viscosity. Ten µg of protein were then subjected to SDS-PAGE electrophoresis, transferred to an Immobilon-P membrane (Millipore), blocked with 5% nonfat powdered milk, and then probed with the appropriate antibodies. Secondary antibodies coupled to horseradish peroxidase were purchased from Cappel. ECL (Amersham) was then performed according to the manufacturer’s protocol.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Ras and Raf, but not MEK, Activate NF-B.
We sought to confirm previous work that had shown that Ras and Raf were capable of activating NF-B-dependent gene expression before investigating the possible requirement for this activation in Ras- and Raf-induced transformation. Expression constructs of RasV12 (a constitutively active mutant of human H-Ras), RafBXB (human Raf-1 in which amino acids 26–302 have been deleted), and MEK (a constitutively active form of human MEK containing S218E and S222D mutations and a deletion of amino acids 32–51) were transfected into NIH 3T3 cells along with a reporter construct, pBIIXluc, which contains two NF-B binding sites from the immunoglobulin enhancer upstream of a minimal promoter and the luciferase gene (4 , 29, 30, 31) . As shown in Fig. 1 , both RasV12 and RafBXB were capable of stimulating NF-B-dependent gene expression by 7.1- and 6.3-fold, respectively. MEK, however, did not induce NF-B-dependent gene expression, suggesting that the activation of NF-B by Ras and Raf was not mediated by the MAPK pathway. As shown in Fig. 1B , RasV12, RafBXB, and MEK were all equally capable of activating MAPK, as shown through the use of an antibody that specifically recognizes the activated (dually phosphorylated) forms of ERK1 and ERK2.

View larger version (23K): [in this window] [in a new window]   Fig. 1. RafBXB and RasV12, but not MEK, activate NF-B-dependent gene expression. A, NIH 3T3 cells were transiently transfected with 100 ng of SRRasV12, SRRafBXB, or pCEP4 MEK, along with 500 ng of the NF-B reporter construct, pBIIXluc, using Lipofectamine (Life Technologies, Inc.). Cells were serum-deprived for 48 h after transfection in 0.5% calf serum and then lysed in 1x reporter lysis buffer (Promega) for measurement of luciferase activities. Vector-alone control is arbitrarily given a luciferase activity of 1 with the activities in the presence of RasV12, RafBXB, or MEK given relative to the vector-alone control. The results represent the means from three independent experiments; bars, SD. B, Western blots of lysates of NIH 3T3 cells transfected with empty vector, RasV12, RafBXB, and MEK. The antibody used in the top panel was anti-active MAPK, which selectively recognizes the dually phosphorylated forms of ERK1 and ERK2, whereas the bottom panel is a control with an anti-ERK1 antibody, which cross-reacts with ERK2. The top band in each case is ERK1, whereas the bottom band is ERK2.

View larger version (16K): [in this window] [in a new window]   Fig. 2. Activation of the pBIIXluc reporter construct by Raf is dependent on NF-B activation. NIH 3T3 cells were transiently transfected with RafBXB as above with or without 100 ng of CMV4 IBN. Results are given as in Fig. 1A with values expressed representing activities relative to the vector alone control. The results represent the means from three independent experiments; bars, SD.

Raf-induced Transformation Requires NF-B Activity.

View larger version (95K): [in this window] [in a new window]   Fig. 3. Dominant-negative IB interferes with transformation of NIH 3T3 cells by RafBXB but not RasV12. NIH 3T3 cells were stably transfected using the calcium phosphate method with empty vector RafBXB, with and without IBN, and RasV12, with and without IBN. Forty-eight h after the transfection, cells were split into two plates containing 5% calf serum for focus assays (and into two plates with 10% calf serum supplemented with 400 µg/ml G418; see Fig. 4 ). The plates containing 5% calf serum were fixed 14 days later in 3.7% formaldehyde and stained with Giemsa in PBS. Foci are visible as densely staining patches.

View larger version (14K): [in this window] [in a new window]   Fig. 4. Dominant-negative IB interferes with transformation of NIH 3T3 cells by RafBXB but not RasV12. A, NIH 3T3 cells were stably transfected using the calcium phosphate method with 100 ng of SRRafBXB alone or with 1 µg of pCMV4 IBN. Forty-eight h after transfection, the cells were split into two plates containing 5% calf serum (Life Technologies, Inc.) for focus assays and two plates with 10% calf serum supplemented with 400 µg/ml G418 (Life Technologies, Inc.) for assaying transfection efficiencies and for assaying the level of expression of proteins. Data are shown as the number of foci relative to RafBXB alone, which is arbitrarily assigned a value of 1. The results are from three independent experiments, each with duplicate samples; bars, SD. B, extracts were prepared from cells selected in G418 (from the above stable transfections in A) using boiling 1% SDS and 10 mM Tris (pH 7.5). Ten µg of protein was then used for Western blots with anti-Raf (Santa Cruz) at a 1:1000 dilution. C, transfections were done as in A but with 100 ng of SRRasV12 in place of SRRafBXB. Data are shown as the number of foci relative to RasV12 alone, which is arbitrarily assigned a value of 1. The results are from three independent experiments, each with duplicate samples; bars, SD.

View larger version (16K): [in this window] [in a new window]   Fig. 5. RafBXB-induced but not RasV12-induced transformation of NIH 3T3 cells is blocked by CrmA, IL-1Ra, and TRAF6. A, NIH 3T3 cells were stably transfected with 100 ng of SRRafBXB alone or with 1 or 2 µg of pCEP4 CrmA, 1 or 2 g of pCEP4 IL1Ra or pcI-neo IL-1Ra, or 1 µg of pRK5 TRAF6 and treated as in Fig. 2A . B, NIH 3T3 cells were stably transfected with 100 ng of pDCR RasV12 or SR RasV12 alone and together with 1 or 3 µg of pCEP4 CrmA, 1 or 3 µg of pCEP4 IL-1Ra or pcI-neo IL-1Ra, or 1 or 3 µg of pRK5 TRAF6 and treated as above. C, using boiling 1% SDS and 10 mM Tris (pH 7.5), extracts were prepared from cells selected in G418 (from the above stable transfections) and used for Western blots with anti-Raf (Santa Cruz) at a 1:1000 dilution. Note that Lanes 1 and 2 are from Fig. 3B .

Activation of NF-B by RafBXB Does Not Require IL-1.

View larger version (19K): [in this window] [in a new window]   Fig. 6. RafBXB-induced activation of NF-B is not dependent upon IL-1. NIH 3T3 cells were transiently transfected as in Fig. 1 with 100 ng of SRRafBXB alone or cotransfected with 100 ng of pCEP4 CrmA, 100 ng of pCEP4 IL-1Ra. Cells were serum deprived for 48 h after transfection in 0.5% calf serum and then lysed in 1x reporter lysis buffer (Promega) for measurement of luciferase activities. Vector alone is arbitrarily given a value of 1, and all other values are expressed relative to it. The results represent the means from three independent experiments; bars, SD.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

The role of IL-1 in transformation was clearly documented by overexpressing IL-1Ra or CrmA. On the basis of the fact that CrmA blocks Raf-induced transformation, it is most likely that IL-1ß is the species of IL-1 involved, but we cannot rule out the possibility that IL-1 is also involved. Although other autocrine growth factors have been found previously to be induced by Raf, this is, to our knowledge, the first identification of an autocrine growth factor identified that is actually required for Raf-induced transformation. In contrast, we found that RasV12-induced transformation of NIH 3T3 cells did not require NF-B activity or an IL-1 autocrine loop. This result may reflect the multiple effector pathways downstream of Ras (29 , 35 , 36) . These may function to transform cells independently of an IL-1 autocrine loop. However, it is also possible that Ras only interacts with and activates such a hypothetical effector pathway because RasV12 was dramatically overexpressed. Consistent with this possibility is the recent finding that activation of endogenous Ras by growth factors led to very little stimulation of PI3K activity, despite the fact that Ras can directly interact with and stimulate the activity of p110, the catalytic subunit of PI3K (36 , 37) . In contrast, it appears that the overexpression of oncogenic Ras is capable of robust stimulation of PI3K, suggesting that artificially high levels of Ras allow it to stimulate signaling pathways that even an endogenous oncogenic form of Ras could not activate (37) . In addition, it has been shown that the transformation of cultured cells in vitro requires 100-fold overexpression of RasV12 as compared with expression levels seen in human tumors expressing RasV12 (38) . An analysis of cancer cell lines that express RasV12 from the endogenous promoter will ultimately serve as a model to determine whether the transformation of cells by RasV12 also requires an IL-1 autocrine loop. Finally, it should be noted that Ras-independent Raf activation has been established to occur in response to a number of different stimuli (38, 39, 40, 41) . The possibility that transformation of cells by such Raf-dependent, Ras-independent pathways may involve an IL-1 autocrine loop requires consideration.

Although it has been reported previously that Raf can directly phosphorylate IB and thereby activate NF-B, this appears unlikely to occur in vivo (42 , 43) . Currently, the mechanism by which Raf activates NF-B is not known, but based on the finding that a constitutively active form of MEK was incapable of activating NF-B in the current studies, it would appear that an alternative effector of Raf may be involved in the activation of NF-B. Although the activated form of MEK used in this study lacks a part of the nuclear exclusion sequence, this form of MEK localizes equally between cytosol and nucleus (44) . Therefore, it is unlikely that MEK failed to activate NF-B, because it is was restricted to the nucleus with no access to the cytosol, where NF-B activation primarily takes place. Other investigators have found that Raf-induced NF-B activation can occur through the activation of the MAPK pathway with a subsequent autocrine growth factor activating the p38 pathway, resulting in the activation of NF-B (45) . In 293 cells, Raf-induced activation of NF-B has been found to occur though the production of an autocrine factor that activates the c-Jun NH₂-terminal kinase pathway and causes the activation of NF-B (46) . Whatever the mechanism by which Raf induces the activation of NF-B, it is significant that this activation is in fact required for Raf to induce transformation of NIH 3T3 cells. It is intriguing to speculate that Raf, a member of the MAPKKK family which also contains NIK and MEKK, two kinases that directly phosphorylate IKK and IKKß, might itself be directly regulating one or more of the IKK enzymes (47 , 48) . In support of the possibility that Raf might physiologically regulate the activity of NF-B rather than just when overexpressed is the finding that Ras and Raf have both been implicated in the activation of NF-B in response to both insulin and hypoxic stress (49 , 50) .

Although Raf has been reported previously to activate pathways other than the MAPK pathway, there has been doubt about whether these events were physiologically relevant because of the difficulty in some cases of reproducing the result or of showing an actual effect on a substrate subsequent to its phosphorylation by Raf. This study confirms that Raf can activate NF-B and that this is an event required for Raf-induced transformation. We cannot rule out that biochemical events other than the activation of MAPK and NF-B are also required for transformation. Thus far, we have not seen cooperation between MEK and other oncogenes that can activate NF-B, such as MEKK, Rac, Rho, or Cdc42 (data not shown). This suggests that pathways downstream of Raf in addition to MAPK and NF-B are required for it to induce transformation. Further work is clearly needed to delineate the mechanisms by which activated Raf induces transformation of NIH 3T3 as well as other cells. However, the current results further suggest that the ability of some genes to cooperate with RafBXB to transform cells may not be simply activating parallel pathways required for transformation but might cooperate with RafBXB at the level of inducing IL-1 or substituting for or mimicking signaling pathways from the IL-1 receptor. Further work will be required to examine this possibility.

The physiological relevance of the current findings is suggested by the finding that NF-B has been found to be constitutively active in a variety of tumor cells, although the reason(s) for this in some tumors is unknown (51) . It is intriguing to speculate that the constitutive activation of Raf by upstream signaling molecules may account for this phenotype, implying biological relevance of the results in NIH 3T3 cells for tumor cells in vivo.

Although further work in other model systems is required before the results of this study can be generalized, it is noteworthy that some tumors appear to use IL-1 as a necessary autocrine growth factor in vivo (52, 53, 54) . Although the nature of the mutations in such cells has not been fully documented, it is possible that they have mutations resulting in the constitutive activation of Raf. It has also been shown, for example, that several cell lines derived from small cell lung carcinoma patient samples show overexpression of Raf at the mRNA and protein level, which results in a high level of Raf activity (55) . Although the mechanism underlying the elevated Raf kinase activity is unknown, it is worth pointing out that Ras genes are rarely mutated in small cell lung carcinoma (56) , thus raising the possibility that activation of Raf might occur independently of Ras activation and that the mechanism of transformation of these tumor cells might involve IL-1 Overall, the current study suggests the possibility that IL-1Ra, or other methods to interfere with IL-1 function, could block the growth of tumor cells in vivo.

	ACKNOWLEDGMENTS

 
We thank Drs. John Abrams, Dean Ballard, Melanie H. Cobb, Sankar Ghosh, David V. Goeddel, and Charles J. Sherr for providing critical reagents. We also thank David V. Goeddel for critical reading of the manuscript.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at NIH, 9000 Rockville Pike, Building 10, Room 9N228, Bethesda, MD 20892-1820. Phone: (301) 496-2612; Fax: (301) 402-0012; E-mail: lipskyp{at}mail.nih.gov

² The abbreviations used are: MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; ERK, extracellular signal-regulated kinase; NF-B, nuclear factor-B; IL, interleukin; IL-1Ra, IL-1 receptor antagonist; PI3K, phosphatidylinositol 3-kinase; IRAK, IL-1R associated kinase; TRAF, tumor necrosis factor receptor-associated factor.

³ Unpublished observations.

Received 12/ 1/99. Accepted 11/ 7/00.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Dent P., Haser W., Haystead T. A. J., Vincent L. A., Roberts T. M., Sturgill T. W. Activation of mitogen-activated protein kinase-kinase by v-Raf in NIH 3T3 cells and in vitro. Science (Washington DC), 257: 1404-1407, 1992.[Abstract/Free Full Text]
2. Howe L. R., Leevers S. J., Gomez N., Nakielny S., Cohen P., Marshall C. J. Activation of the MAP kinase pathway by the protein kinase Raf. Cell, 71: 335-342, 1992.[Medline]
3. Kyriakis J. M., App H., Zhang X., Banerjee P., Brautigan D. L., Rapp U. R., Avruch J. Raf-1 activates MAP kinase-kinase. Nature (Lond.), 358: 417-421, 1992.[Medline]
4. Bruder J. T., Heidecker G., Rapp U. R. Serum-, TPA-, and Ras-induced expression from AP-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev., 6: 545-556, 1992.[Abstract/Free Full Text]
5. Finco T., Baldwin A. B site-dependent induction of gene expression by diverse inducers of nuclear factor B requires Raf-1. J. Biol. Chem., 268: 17676-17679, 1993.[Abstract/Free Full Text]
6. Galaktionov K., Jessus C., Beach D. Raf-1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev., 9: 1046-1058, 1995.[Abstract/Free Full Text]
7. Lenormand P., McMahon M., Pouyssegur J. Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. J. Biol. Chem., 271: 15762-15768, 1996.[Abstract/Free Full Text]
8. May M. J., Ghosh S. Rel/NF-B and IB proteins: an overview. Semin. Cancer Biol., 8: 63-73, 1997.[Medline]
9. Huxford T., Huang D. B., Malek S., Ghosh G. The crystal structure of the IB/NF-B complex reveals mechanisms of NF-B inactivation. Cell, 95: 759-770, 1998.[Medline]
10. Jacobs M. D., Harrison S. C. Structure of an IB/NF-B complex. Cell, 95: 749-758, 1998.[Medline]
11. DiDonato J. A., Hayakawa M., Rothwarf D. M., Zandi E., Karin M. A cytokine-responsive IB kinase that activates the transcription factor NF-B. Nature (Lond.), 388: 548-554, 1997.[Medline]
12. Mercurio F., Zhu H., Murray B. W., Shevchenko A., Bennett B. L., Li J., Young D. B., Barbosa M., Mann M., Manning A., Rao A. F. IKK-1 and IKK-2: cytokine-activated IB kinases essential for NF-B activation. Science (Washington DC), 278: 860-866, 1997.[Abstract/Free Full Text]
13. Regnier C. H., Song H. Y., Gao X., Goeddel D. V., Cao Z., Rothe M. Identification and characterization of an IB kinase. Cell, 90: 373-383, 1997.[Medline]
14. Woronicz J. D., Gao X., Cao Z., Rothe M., Goeddel D. V. IB kinase-ß NF-B activation and complex formation with IB kinase and NIK. Science (Washington DC), 278: 866-869, 1997.[Abstract/Free Full Text]
15. Zandi E., Rothwarf D. M., Delhase M., Hayakawa M., Karin M. The IB kinase complex (IKK) contains two kinase subunits, IKK and IKKß, necessary for IB phosphorylation and NF-B activation. Cell, 91: 243-252, 1997.[Medline]
16. Zandi E., Chen Y., Karin M. Direct phosphorylation of IB by IKK and IKKß: discrimination between free and NF-B-bound substrate. Science (Washington DC), 281: 1360-1363, 1998.[Abstract/Free Full Text]
17. Barnes P. J., Karin M. Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 336: 1066-1071, 1997.[Free Full Text]
18. Cogswell J. P., Godlevski M. M., Wisely G. B., Clay W. C., Leesnitzer L. M., Ways J. P., Gray J. G. NF-B regulates IL-1ß transcription through a consensus NF-B binding site and nonconsensus CRE-like site. J. Immunol., 153: 712-723, 1994.[Abstract]
19. Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood, 87: 2095-2147, 1996.[Abstract/Free Full Text]
20. Hiscott J., Marois J., Garoufalis J., D’Addario M., Roulston A., Kwan I., Pepin N., Lacoste J., Nguyen H., Bensi G., Fenton M. Characterization of a functional NF-B site in the human interleukin 1ß promoter: evidence for a positive autoregulatory loo. p. Mol. Cell. Biol., 13: 6231-6240, 1993.[Abstract/Free Full Text]
21. Dinarello C. A., Margolis N. H. Stopping the cuts: cytokine-processing enzymes. Curr. Biol., 5: 587-590, 1995.[Medline]
22. March C. J., Mosley B., Larsen A., Cerretti D. P., Braedt G., Price V., Gillis S., Henney C. S., Kronheim S. R., Grabstein K., Conlon P. J., Hopp T. P., Cosman D. Cloning, sequence, and expression of two distinct human interleukin-1 complementary DNAs. Nature (Lond.), 315: 641-647, 1985.[Medline]
23. Mathias S., Younes A., Kan C. C., Orlow I., Joseph C., Kolesnick R. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1ß. Science (Washington DC), 259: 519-522, 1993.[Abstract/Free Full Text]
24. O’Neill L. A., Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J. Leukocyte Biol., 63: 650-657, 1998.[Abstract]
25. Reddy S. A., Huang J. H., Liao W. S-L. Phosphatidylinositol 3-kinase in interleukin 1 signaling. J. Biol. Chem., 272: 29167-29173, 1997.[Abstract/Free Full Text]
26. Cao, Z., Henzel, W. J., and Gao, X. IRAK. A kinase associated with the interleukin-1 receptor. Science (Washington DC), 271: 1128–1131, 1996.
27. Muzio M., Ni J., Feng P., Dixit V. M. IRAK (Pelle) family members IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (Washington DC), 278: 1612-1615, 1997.[Abstract/Free Full Text]
28. Cao Z., Xiong J., Takeuchi M., Kurama T., Goeddel D. V. TRAF6 is a signal transducer for interleukin-1. Nature (Lond.), 383: 443-446, 1996.[Medline]
29. White M. A., Nicolette C., Minden A., Polverino A., van Aelst L., Karin M., Wigler M. H. Multiple Ras functions can contribute to mammalian cell transformation. Cell, 80: 533-541, 1995.[Medline]
30. Kopp E., Ghosh S. Inhibition of NF-B by sodium salicylate and aspirin. Science (Washington DC), 265: 956-959, 1994.[Abstract/Free Full Text]
31. Mansour S. J., Matten W. T., Hermann A. S., Candia J. M., Rong S., Fukasawa K., Vande Woude G. F., Ahn N. G. Transformation of mammalian cells by constitutively active MAP kinase-kinase. Science (Washington DC), 265: 966-970, 1994.[Abstract/Free Full Text]
32. Brockman J. A., Scherer D. C., McKinsey T. A., Hall S. M., Qi S., Lee W. Y., Ballard D. W. Coupling of a signal response domain in IB to multiple pathways for NF-B activation. Mol. Cell. Biol., 13: 2809-2818, 1995.
33. Ray C. A., Black R. A., Kronheim S. R., Greenstreet T. A., Sleath P. R., Salvesen G. S., Pickup D. J. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1ß converting enzyme. Cell, 69: 597-604, 1992.[Medline]
34. Matsushime H., Roussel M. F., Matsushima K., Hishinuma A., Sherr C. J. Cloning and expression of murine interleukin-1 receptor antagonist in macrophages stimulated by colony-stimulating factor 1. Blood, 78: 616-623, 1991.[Abstract/Free Full Text]
35. Marshall M. S. Ras target proteins in eukaryotic cells. FASEB J., 9: 1311-1318, 1995.[Abstract]
36. Rodriguez-Viciana P., Warne P., Khwaja A., Marte B., Pappin D., Ridley A., Downward J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell, 89: 457-467, 1997.[Medline]
37. van Weering D. H., de Rooij J., Marte B., Downward J., Bos J. L., Burgering B. M. T. Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. Mol. Cell. Biol., 18: 1802-1811, 1998.[Abstract/Free Full Text]
38. Hua V. Y., Wang W. K., Duesberg P. H. Dominant transformation by mutated human ras genes in vitro requires more than 100 times higher expression than is observed in cancers. Proc. Natl. Acad. Sci. USA, 94: 9614-9619, 1997.[Abstract/Free Full Text]
39. Arai H., Escobedo J. A. Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism. Mol. Pharmacol., 50: 522-528, 1996.[Abstract]
40. Morrison D. K. Mechanisms regulating Raf-1 activity in signal transduction pathways. Mol. Reprod. Dev., 42: 507-514, 1995.[Medline]
41. Takahashi T., Ueno H., Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene, 18: 2221-2230, 1999.[Medline]
42. Janosch P., Schellerer M., Seitz T., Reim P., Eulitz M., Brielmeier M., Kolch W., Sedivy J. M., Mischak H. Characterization of IB kinases. J. Biol. Chem., 271: 13868-13874, 1996.[Abstract/Free Full Text]
43. Li S., Sedivy J. M. Raf-1 protein kinase activates the NF-B transcription factor by dissociating the cytoplasmic NF-B-IB complex. Proc. Natl. Acad. Sci. USA, 90: 9247-9251, 1993.[Abstract/Free Full Text]
44. Fukuda M., Gotoh I., Adachi J., Gotoh Y., Nishida E. A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. J. Biol. Chem., 272: 32642-32648, 1997.[Abstract/Free Full Text]
45. Norris J. L., Baldwin A. S. Oncogenic Ras enhances NF-B transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J. Biol. Chem., 274: 13841-13846, 1999.[Abstract/Free Full Text]
46. Troppmair J., Hartkamp J., Rapp U. R. Activation of NF-B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade. Oncogene, 17: 685-690, 1998.[Medline]
47. Lee F. S., Peters R. T., Dang L. C., Maniatis T. MEKK1 activates both IB kinase and IB kinase ß. Proc. Natl. Acad. Sci. USA, 95: 9319-9324, 1998.[Abstract/Free Full Text]
48. Ling L., Cao Z., Goeddel D. V. NF-B-inducing kinase activates IKK by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA, 95: 3792-3797, 1998.[Abstract/Free Full Text]
49. Bertrand F., Philippe C., Antoine P. J., Baud L., Groyer A., Capeau J., Cherqui G. Insulin activates nuclear factor B in mammalian cells through a Raf-1-mediated pathway. J. Biol. Chem., 270: 24435-24441, 1995.[Abstract/Free Full Text]
50. Koong A. C., Chen E. Y., Mivechi N. F., Denko N. C., Stambrook P., Giaccia A. J. Hypoxic activation of nuclear factor-B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res., 54: 5273-5279, 1994.[Abstract/Free Full Text]
51. Wulczyn F. G., Krappmann D., Scheidereit C. The NF-B/Rel and IB gene families: mediators of immune response and inflammation. J. Mol. Med., 74: 749-769, 1996.[Medline]
52. Burrows F. J., Haskard D. O., Hart I. R., Marshall J. F., Selkirk S., Poole S., Thorpe P. E. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res., 51: 4768-4775, 1991.[Abstract/Free Full Text]
53. Busson P., Braham K., Ganem G., Thomas F., Grausz D., Lipinski M., Wakasugi H., Tursz T. Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1. Proc. Natl. Acad. Sci. USA, 84: 6262-6266, 1987.[Abstract/Free Full Text]
54. Estrov Z., Kurzrock R., Wetzler M., Kantarjian H., Blake M., Harris D., Gutterman J. U., Talpaz M. Suppression of chronic myelogenous leukemia colony growth by IL-1 receptor antagonist and soluble IL-1 receptors: a novel mechanism of chronic myelogenous leukemia progression. Blood, 78: 1476-1484, 1991.[Abstract/Free Full Text]
55. Rapp U. R., Storm S. M., Cleveland J. L. Oncogenes: clinical relevance. Hamatol. Bluttransfus., 31: 450-459, 1987.[Medline]
56. Sekido Y., Fong K. M., Minna J. D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta, 1378: F21-F59, 1998.[Medline]

This article has been cited by other articles:

				I. Palona, H. Namba, N. Mitsutake, D. Starenki, A. Podtcheko, I. Sedliarou, A. Ohtsuru, V. Saenko, Y. Nagayama, K. Umezawa, et al. BRAFV600E Promotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor {kappa}B Activation Endocrinology, December 1, 2006; 147(12): 5699 - 5707. [Abstract] [Full Text] [PDF]

				A. Schulze, B. Nicke, P. H. Warne, S. Tomlinson, and J. Downward The Transcriptional Response to Raf Activation Is Almost Completely Dependent on Mitogen-activated Protein Kinase Kinase Activity and Shows a Major Autocrine Component Mol. Biol. Cell, July 1, 2004; 15(7): 3450 - 3463. [Abstract] [Full Text] [PDF]

				T. Ikenoue, Y. Hikiba, F. Kanai, J. Aragaki, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, et al. Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor {kappa}B Pathway and Cellular Transformation Cancer Res., May 15, 2004; 64(10): 3428 - 3435. [Abstract] [Full Text] [PDF]

				J. Niu, Z. Li, B. Peng, and P. J. Chiao Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1{alpha} in Induction of Constitutive NF-{kappa}B Activation in Pancreatic Cancer Cells J. Biol. Chem., April 16, 2004; 279(16): 16452 - 16462. [Abstract] [Full Text] [PDF]

				T. Ikenoue, Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, T. Kawakami, et al. Functional Analysis of Mutations within the Kinase Activation Segment of B-Raf in Human Colorectal Tumors Cancer Res., December 1, 2003; 63(23): 8132 - 8137. [Abstract] [Full Text] [PDF]

				J.-E. Murphy, R. E. Morales, J. Scott, and T. S. Kupper IL-1{alpha}, Innate Immunity, and Skin Carcinogenesis: The Effect of Constitutive Expression of IL-1{alpha} in Epidermis on Chemical Carcinogenesis J. Immunol., June 1, 2003; 170(11): 5697 - 5703. [Abstract] [Full Text] [PDF]

				A. S. Dhillon, S. Meikle, C. Peyssonnaux, J. Grindlay, C. Kaiser, H. Steen, P. E. Shaw, H. Mischak, A. Eychene, and W. Kolch A Raf-1 Mutant That Dissociates MEK/Extracellular Signal-Regulated Kinase Activation from Malignant Transformation and Differentiation but Not Proliferation Mol. Cell. Biol., March 15, 2003; 23(6): 1983 - 1993. [Abstract] [Full Text] [PDF]

				J.-I. Park, C. J. Strock, D. W. Ball, and B. D. Nelkin The Ras/Raf/MEK/Extracellular Signal-Regulated Kinase Pathway Induces Autocrine-Paracrine Growth Inhibition via the Leukemia Inhibitory Factor/JAK/STAT Pathway Mol. Cell. Biol., January 15, 2003; 23(2): 543 - 554. [Abstract] [Full Text] [PDF]

				J. J. Fiordalisi, S. P. Holly, R. L. Johnson II, L. V. Parise, and A. D. Cox A Distinct Class of Dominant Negative Ras Mutants. CYTOSOLIC GTP-BOUND Ras EFFECTOR DOMAIN MUTANTS THAT INHIBIT Ras SIGNALING AND TRANSFORMATION AND ENHANCE CELL ADHESION J. Biol. Chem., March 22, 2002; 277(13): 10813 - 10823. [Abstract] [Full Text] [PDF]

				A. Arlt, J. Vorndamm, S. Muerkoster, H. Yu, W. E. Schmidt, U. R. Folsch, and H. Schafer Autocrine Production of Interleukin 1{beta} Confers Constitutive Nuclear Factor {kappa}B Activity and Chemoresistance in Pancreatic Carcinoma Cell Lines Cancer Res., February 1, 2002; 62(3): 910 - 916. [Abstract] [Full Text] [PDF]

				J. S. Wolf, Z. Chen, G. Dong, J. B. Sunwoo, C. C. Bancroft, D. E. Capo, N. T. Yeh, N. Mukaida, and C. V. Waes IL (Interleukin)-1{{alpha}} Promotes Nuclear Factor-{{kappa}}B and AP-1-induced IL-8 Expression, Cell Survival, and Proliferation in Head and Neck Squamous Cell Carcinomas Clin. Cancer Res., June 1, 2001; 7(6): 1812 - 1820. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vale, T. Articles by Lipsky, P. E. Search for Related Content PubMed PubMed Citation Articles by Vale, T. Articles by Lipsky, P. E.